Advancing towards accurate phenotyping based on metabolic and fibrosis risk in metabolic-dysfunction associated steatotic liver disease: one step closer to personalized care

Hepatobiliary Surg Nutr. 2024 Feb 1;13(1):128-131. doi: 10.21037/hbsn-23-563. Epub 2024 Jan 18.

Authors

Sergio Muñoz-Martínez^{1

2}, Alba Jiménez-Masip^{1

3}, Juan M Pericàs^{1

3

4}

Affiliations

¹ Liver Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
² Universitat de Barcelona, Barcelona, Spain.
³ Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.
⁴ Centros de Investigación Biomédica en Red, Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.

No abstract available

Keywords: Metabolic-dysfunction associated steatotic liver disease (MASLD); advanced fibrosis; non-invasive tests (NITs); type 2 diabetes (T2D).

Publication types

Editorial
Comment